View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAcuCort 将来の成長Future 基準チェック /06現在、 AcuCortの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 22AcuCort AB (publ) to Report Fiscal Year 2025 Results on Feb 20, 2026AcuCort AB (publ) announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on Feb 20, 2026分析記事 • Dec 03AcuCort (BST:NV5) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr2.37m (up 36% from 3Q 2024). Net loss: kr5.34m (loss widened 115% from 3Q 2024).お知らせ • Oct 16AcuCort AB (publ) to Report Q3, 2025 Results on Nov 14, 2025AcuCort AB (publ) announced that they will report Q3, 2025 results on Nov 14, 2025お知らせ • Oct 15AcuCort Appoints Anna Chérouvrier Hansson as Business Development DirectorAcuCort has appointed Anna Chérouvrier Hansson as its Business Development Director. The appointment is part of AcuCort's continued commercial development and focus on strengthening strategic partnerships to support the launch of Zeqmelit® in additional markets.Anna Chérouvrier Hansson brings more than 15 years of experience in business development, sales and marketing within the life science sector. She has held senior positions in both listed companies and fast-growing SMEs, including SenzaGen and Camurus.At SenzaGen, she played a key role in building and driving the company's business development and commercialisation strategy, establishing a global network of licensees and distributors, and negotiating international agreements. At Camurus, she was instrumental in the launch of the company's first commercial product in supportive cancer care across several international markets.Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr1.34m (up 5.3% from 2Q 2024). Net loss: kr7.57m (loss widened 99% from 2Q 2024).分析記事 • Aug 16We're Hopeful That AcuCort (BST:NV5) Will Use Its Cash WiselyBST:NV5 1 Year Share Price vs Fair Value Explore AcuCort's Fair Values from the Community and select yours There's no...お知らせ • Jul 21AcuCort AB (publ) to Report Q2, 2025 Results on Aug 19, 2025AcuCort AB (publ) announced that they will report Q2, 2025 results on Aug 19, 2025Reported Earnings • Apr 20Full year 2024 earnings releasedFull year 2024 results: Revenue: kr7.72m (up 17% from FY 2023). Net loss: kr17.4m (loss widened 27% from FY 2023).お知らせ • Apr 09AcuCort AB (publ) to Report Q1, 2025 Results on May 08, 2025AcuCort AB (publ) announced that they will report Q1, 2025 results on May 08, 2025お知らせ • Mar 20AcuCort Receives Renewed Marketing Authorisation for Zeqmelit® in NorwayAcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit® from the Norwegian Medical Products Agency (Direktoratet for medisinske produkter), Norway's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation. AcuCort was first granted a marketing authorisation for Zeqmelit® in Norway in 2022. That approval was time-limited, which is standard for new medicines. Following an application for renewal, the Norwegian Medical Products Agency has now granted an extended marketing authorisation for the Norwegian market, this time without a time restriction.お知らせ • Mar 19AcuCort Receives Renewed Marketing Authorisation for Zeqmelit® in DenmarkAcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit from the Danish Medicines Agency (Laegemiddelstyrelsen), Denmark's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation. AcuCort was first granted a marketing authorisation for Zeqmelit in Denmark in 2022. That approval was time-limited, which is standard for new medicines. Now, following an inspection by the Swedish Medical Products Agency, the Danish Medicines Agency has granted an extended marketing authorisation, this time without a time limitation.お知らせ • Mar 05AcuCort AB (publ) Receives Renewed Marketing Authorisation from the Swedish Medical Products AgencyAcuCort AB (publ) has received renewed marketing authorisation for its medicinal product Zeqmelit® from the Swedish Medical Products Agency. The decision is valid indefinitely. AcuCort applied for and was granted marketing authorization for its medicinal product in 2020. That authorization was valid for a period of five years, which is standard practice for new medicines. As a result, AcuCort applied for an extension, and the Swedish Medical Products Agency has now granted renewed marketing authorisation, effective from 6 October 2025. This time, the authorisation is valid without time limitation.お知らせ • Jan 23AcuCort AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025AcuCort AB (publ) announced that they will report fiscal year 2024 results on Feb 21, 2025New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 14% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$629k). Market cap is less than US$10m (€6.94m market cap, or US$7.14m).Reported Earnings • Dec 04Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: kr1.74m (up 1.2% from 3Q 2023). Net loss: kr2.48m (loss narrowed 21% from 3Q 2023).New Risk • Nov 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr25m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (281% increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$642k). Market cap is less than US$10m (€7.40m market cap, or US$7.83m).お知らせ • Nov 14All Patients Completed AcuCort's Phase IV Study ZEQ001AcuCort's Phase IV study, ZEQ001, began in late January 2024. This study enrolled 50 patients, and the last participant has now completed it. The study findings are intended to be published in scientific journals, providing key support for AcuCort's upcoming launch initiatives. A key objective of the study, an open, non-randomised, low-intervention study, is to obtain scientific data from patients who previously used tablets but, in the study, are using Zeqmelit® instead. The study will answer essential questions, such as whether patients feel confident with Zeqmelit®, what the experience of using the medication is like, and whether they carry it with them. The study results will be published in scientific journals, thereby providing crucial support for the launch of Zeqmelit® in selected markets.お知らせ • Oct 24AcuCort AB (publ) to Report Q3, 2024 Results on Nov 22, 2024AcuCort AB (publ) announced that they will report Q3, 2024 results on Nov 22, 2024お知らせ • Sep 03Acucort AB (Publ) Announces Launch of Zeqmelit®? Initiated - Now Available At PharmaciesAcuCort has previously announced that the market launch of Zeqmelit®? would begin in early September. In line with this plan, Zeqmelit®? is available at Swedish pharmacies starting on September 2nd. The product will soon also be available at pharmacies in Norway and Finland. The launch is proceeding exactly as planned, and have thus achieved yet another important milestone. Physicians can prescribe Zeqmelit®?, and the product is now available at Swedish pharmacies. It will soon also be available at hospitals in Norway and Finland.お知らせ • Jul 25AcuCort AB (publ) to Report First Half, 2024 Results on Aug 23, 2024AcuCort AB (publ) announced that they will report first half, 2024 results on Aug 23, 2024Board Change • Jun 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Monica Wallter was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 12AcuCort AB (publ) to Report Q3, 2023 Results on Nov 10, 2023AcuCort AB (publ) announced that they will report Q3, 2023 results on Nov 10, 2023お知らせ • Jul 13AcuCort AB (publ) to Report Q2, 2023 Results on Aug 11, 2023AcuCort AB (publ) announced that they will report Q2, 2023 results on Aug 11, 2023 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、AcuCort は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BST:NV5 - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20259-27-23-15N/A6/30/20258-24-22-15N/A3/31/20258-20-23-15N/A12/31/20248-17-27-20N/A9/30/20247-14-26-20N/A6/30/20247-15-25-18N/A3/31/20247-14-24-17N/A12/31/20237-14-18-12N/A9/30/20236-13-19-12N/A6/30/20235-14-19-14N/A3/31/20235-15-20-15N/A12/31/20225-15-19-14N/A9/30/20225-14-19-13N/A6/30/20225-13-18-13N/A3/31/20224-13-17-14N/A12/31/20213-11-14-10N/A9/30/20211-10-12-10N/A6/30/20211-9-10-9N/A3/31/20211-8-9-7N/A12/31/20202-8-10-8N/A9/30/20206-8N/AN/AN/A6/30/20205-9N/AN/AN/A3/31/20205-9N/AN/AN/A12/31/20194-8N/AN/AN/A9/30/2019N/A-8N/AN/AN/A6/30/2019N/A-6N/AN/AN/A3/31/2019N/A-6N/AN/AN/A12/31/2018N/A-6N/AN/AN/A9/30/2018N/A-5N/AN/AN/A6/30/2018N/A-5N/AN/AN/A3/31/2018N/A-5N/AN/AN/A12/31/2017N/A-5N/AN/AN/A9/30/2017N/A-5N/AN/AN/A6/30/2017N/A-4N/AN/AN/A3/31/2017N/A-3N/AN/AN/A12/31/2016N/A-2N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NV5の予測収益成長が 貯蓄率 ( 1.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NV5の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NV5の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NV5の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NV5の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NV5の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/12 11:30終値2026/02/09 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AcuCort AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 22AcuCort AB (publ) to Report Fiscal Year 2025 Results on Feb 20, 2026AcuCort AB (publ) announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on Feb 20, 2026
分析記事 • Dec 03AcuCort (BST:NV5) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr2.37m (up 36% from 3Q 2024). Net loss: kr5.34m (loss widened 115% from 3Q 2024).
お知らせ • Oct 16AcuCort AB (publ) to Report Q3, 2025 Results on Nov 14, 2025AcuCort AB (publ) announced that they will report Q3, 2025 results on Nov 14, 2025
お知らせ • Oct 15AcuCort Appoints Anna Chérouvrier Hansson as Business Development DirectorAcuCort has appointed Anna Chérouvrier Hansson as its Business Development Director. The appointment is part of AcuCort's continued commercial development and focus on strengthening strategic partnerships to support the launch of Zeqmelit® in additional markets.Anna Chérouvrier Hansson brings more than 15 years of experience in business development, sales and marketing within the life science sector. She has held senior positions in both listed companies and fast-growing SMEs, including SenzaGen and Camurus.At SenzaGen, she played a key role in building and driving the company's business development and commercialisation strategy, establishing a global network of licensees and distributors, and negotiating international agreements. At Camurus, she was instrumental in the launch of the company's first commercial product in supportive cancer care across several international markets.
Reported Earnings • Aug 19Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr1.34m (up 5.3% from 2Q 2024). Net loss: kr7.57m (loss widened 99% from 2Q 2024).
分析記事 • Aug 16We're Hopeful That AcuCort (BST:NV5) Will Use Its Cash WiselyBST:NV5 1 Year Share Price vs Fair Value Explore AcuCort's Fair Values from the Community and select yours There's no...
お知らせ • Jul 21AcuCort AB (publ) to Report Q2, 2025 Results on Aug 19, 2025AcuCort AB (publ) announced that they will report Q2, 2025 results on Aug 19, 2025
Reported Earnings • Apr 20Full year 2024 earnings releasedFull year 2024 results: Revenue: kr7.72m (up 17% from FY 2023). Net loss: kr17.4m (loss widened 27% from FY 2023).
お知らせ • Apr 09AcuCort AB (publ) to Report Q1, 2025 Results on May 08, 2025AcuCort AB (publ) announced that they will report Q1, 2025 results on May 08, 2025
お知らせ • Mar 20AcuCort Receives Renewed Marketing Authorisation for Zeqmelit® in NorwayAcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit® from the Norwegian Medical Products Agency (Direktoratet for medisinske produkter), Norway's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation. AcuCort was first granted a marketing authorisation for Zeqmelit® in Norway in 2022. That approval was time-limited, which is standard for new medicines. Following an application for renewal, the Norwegian Medical Products Agency has now granted an extended marketing authorisation for the Norwegian market, this time without a time restriction.
お知らせ • Mar 19AcuCort Receives Renewed Marketing Authorisation for Zeqmelit® in DenmarkAcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit from the Danish Medicines Agency (Laegemiddelstyrelsen), Denmark's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation. AcuCort was first granted a marketing authorisation for Zeqmelit in Denmark in 2022. That approval was time-limited, which is standard for new medicines. Now, following an inspection by the Swedish Medical Products Agency, the Danish Medicines Agency has granted an extended marketing authorisation, this time without a time limitation.
お知らせ • Mar 05AcuCort AB (publ) Receives Renewed Marketing Authorisation from the Swedish Medical Products AgencyAcuCort AB (publ) has received renewed marketing authorisation for its medicinal product Zeqmelit® from the Swedish Medical Products Agency. The decision is valid indefinitely. AcuCort applied for and was granted marketing authorization for its medicinal product in 2020. That authorization was valid for a period of five years, which is standard practice for new medicines. As a result, AcuCort applied for an extension, and the Swedish Medical Products Agency has now granted renewed marketing authorisation, effective from 6 October 2025. This time, the authorisation is valid without time limitation.
お知らせ • Jan 23AcuCort AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025AcuCort AB (publ) announced that they will report fiscal year 2024 results on Feb 21, 2025
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 14% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$629k). Market cap is less than US$10m (€6.94m market cap, or US$7.14m).
Reported Earnings • Dec 04Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: kr1.74m (up 1.2% from 3Q 2023). Net loss: kr2.48m (loss narrowed 21% from 3Q 2023).
New Risk • Nov 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr25m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (281% increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$642k). Market cap is less than US$10m (€7.40m market cap, or US$7.83m).
お知らせ • Nov 14All Patients Completed AcuCort's Phase IV Study ZEQ001AcuCort's Phase IV study, ZEQ001, began in late January 2024. This study enrolled 50 patients, and the last participant has now completed it. The study findings are intended to be published in scientific journals, providing key support for AcuCort's upcoming launch initiatives. A key objective of the study, an open, non-randomised, low-intervention study, is to obtain scientific data from patients who previously used tablets but, in the study, are using Zeqmelit® instead. The study will answer essential questions, such as whether patients feel confident with Zeqmelit®, what the experience of using the medication is like, and whether they carry it with them. The study results will be published in scientific journals, thereby providing crucial support for the launch of Zeqmelit® in selected markets.
お知らせ • Oct 24AcuCort AB (publ) to Report Q3, 2024 Results on Nov 22, 2024AcuCort AB (publ) announced that they will report Q3, 2024 results on Nov 22, 2024
お知らせ • Sep 03Acucort AB (Publ) Announces Launch of Zeqmelit®? Initiated - Now Available At PharmaciesAcuCort has previously announced that the market launch of Zeqmelit®? would begin in early September. In line with this plan, Zeqmelit®? is available at Swedish pharmacies starting on September 2nd. The product will soon also be available at pharmacies in Norway and Finland. The launch is proceeding exactly as planned, and have thus achieved yet another important milestone. Physicians can prescribe Zeqmelit®?, and the product is now available at Swedish pharmacies. It will soon also be available at hospitals in Norway and Finland.
お知らせ • Jul 25AcuCort AB (publ) to Report First Half, 2024 Results on Aug 23, 2024AcuCort AB (publ) announced that they will report first half, 2024 results on Aug 23, 2024
Board Change • Jun 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Monica Wallter was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 12AcuCort AB (publ) to Report Q3, 2023 Results on Nov 10, 2023AcuCort AB (publ) announced that they will report Q3, 2023 results on Nov 10, 2023
お知らせ • Jul 13AcuCort AB (publ) to Report Q2, 2023 Results on Aug 11, 2023AcuCort AB (publ) announced that they will report Q2, 2023 results on Aug 11, 2023